AI And Portable Imaging Will Advance Global Healthcare Diagnostics

Key Takeaways

• Expanding enterprise deals, clinical AI apps, and HomeCare pilots position Butterfly for growth in recurring digital revenue aligned with decentralized, accessible healthcare trends.
  
• Product and software innovations, cost reductions, and successful commercialization efforts support higher adoption, improved gross margins, and pave the way to scalable profitability.
  
• Sluggish domestic growth, global revenue volatility, high R&D expenses, and executive instability threaten profitability and undermine financial performance and customer retention.

Catalysts

Develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally.

• Butterfly's pipeline of large enterprise and medical school deals, bolstered by recent success in landing a top global health system for full deployment, points to accelerating penetration of handheld ultrasound solutions as healthcare systems shift toward more accessible, cost-effective, point-of-care diagnostics-supporting forward-looking revenue growth as funding clarity returns.
  
• The launch of next-generation Compass AI software, with automated documentation and workflow enhancements, is expected to drive increased enterprise adoption and higher software subscription revenues, improving gross margin mix and boosting earnings via a greater share of recurring, high-margin digital revenue.
  
• Commercialization of Butterfly Garden's clinical AI apps (e.g., HeartFocus, iCardio) expands the addressable market by enabling health professionals without prior ultrasound training to perform advanced diagnostics, catalyzing device sales, software adoption, and new recurring revenue streams-directly aligned with rising global demand for affordable, scalable healthcare solutions.
  
• Progress on the HomeCare pilot, targeting large populations of heart failure patients with portable, AI-assisted ultrasound and remote specialist diagnosis, validates Butterfly's unique position to capitalize on the healthcare trend toward preventive, decentralized care, with the potential to generate significant new revenue and improve net margins as contracts expand state
• and nation-wide.
  
• Ongoing advances in semiconductor manufacturing, new product launches (e.g., iQ Station, upcoming fourth-generation P5 technology), and cost containment efforts are driving product miniaturization and lower production costs, supporting higher gross margins and a credible path to sustainable profitability at scale as portable imaging adoption accelerates globally.

Butterfly Network Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Butterfly Network's revenue will grow by 22.5% annually over the next 3 years.
• Analysts are not forecasting that Butterfly Network will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Butterfly Network's profit margin will increase from -66.7% to the average US Medical Equipment industry of 12.1% in 3 years.
• If Butterfly Network's profit margin were to converge on the industry average, you could expect earnings to reach $25.0 million (and earnings per share of $0.08) by about August 2029, up from -$74.8 million today.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 145.9x on those 2029 earnings, up from -31.4x today. This future PE is greater than the current PE for the US Medical Equipment industry at 26.2x.
• Analysts expect the number of shares outstanding to grow by 5.78% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.49%, as per the Simply Wall St company report.

Risks

• Persistent delays in closing large enterprise and medical school deals, along with extended sales cycles due to healthcare funding uncertainty and changes in government programs, may lead to lower-than-expected revenue growth as customers defer capital spending.
  
• Flat domestic revenue and lower renewal rates for individual software subscriptions suggest Butterfly may struggle with customer stickiness and retention in its core market, which could pressure both recurring revenue and net margins.
  
• Reliance on growth in international markets, coupled with disruptions and pauses in global health projects due to cuts in NGO/public funding, introduces volatility and unpredictable revenue streams, potentially impacting overall earnings stability.
  
• Ongoing high R&D and investment needs to advance AI and semiconductor technology (including P5 development and new software platforms) could result in continued operating losses and delay breakeven, negatively affecting profitability and earnings per share.
  
• Transition in executive leadership, including the departure of the CFO and dependence on an interim replacement during a critical execution period, could disrupt strategic focus and operational continuity, potentially impacting financial performance and investor confidence.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $9.31 for Butterfly Network based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $11.0, and the most bearish reporting a price target of just $5.25.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $206.0 million, earnings will come to $25.0 million, and it would be trading on a PE ratio of 145.9x, assuming you use a discount rate of 7.5%.
• Given the current share price of $8.84, the analyst price target of $9.31 is 5.1% higher. The relatively low difference between the current share price and the analyst consensus price target indicates that they believe on average, the company is fairly priced.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.